Methods and compositions for impairing multiplication of hiv-1
CA 2406746 A1 · Owner: Thymon L.L.C. · Inventors: Goldstein, Gideon
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A composition which elicits antibodies to most (e.g. greater than 95 %) of the known variants of Tat protein of HIV-1 of both the B and non-B clades contains at least two variants of a peptide or polypeptide of the formula: R1- Asp-Pro-Y7-Leu-X9-Pro-Trp-Z12-R2 SEQ ID NO:8. According to this formula Y7 , is Arg, Lys, Ser or Asn; X9 is Glu or Asp; Z12 is Lys or Asn; R1 is hydrogen a lower alkyl, a lower alkanoyl, or a sequence of between 1 to about 5 amino acids, optionally substituted with a lower alkyl or lower alkanoyl; and R2 is a free hydroxyl, an amide, or a sequence of one or up to about 5 additional amino acids, optionally substituted with an amide. In this composition at , least …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 20, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 20, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 20, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.